Search
Isoxicam
go.drugbank.com/drugs/DB08942ApprovedWithdrawnIsoxicam is a non-steroidal anti-inflammatory drug that is not marketed in the United States.
DLO6002
go.drugbank.com/drugs/DB05179ExperimentalDLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.
Gantacurium
go.drugbank.com/drugs/DB05710InvestigationalGantacurium chloride is a new, investigational, non-depolarizing ultra-short acting neuromuscular blocker. It is being developed by Avera Pharmaceuticals.
Prulifloxacin
go.drugbank.com/drugs/DB11892InvestigationalPrulifloxacin has been investigated for the treatment of Urinary Tract Infection.
Categories: Topoisomerase II InhibitorsLight green SF yellowish
go.drugbank.com/drugs/DB11183ApprovedLight green SF yellowish is a green triarylmethane dye that is used in the preparation of the staining solution which is widely used as a counterstain. … It is used in histological applications and other labratory settings, and usually exists as a disodium salt. The maximum absorption of light green SF yellowish is at 630 (422) nm.
Biapenem
go.drugbank.com/drugs/DB13028InvestigationalIt is a carbapenem antibiotic with a methyl group on the 1-beta position, which gives it stability against degradation by dehydropeptidase I.[A275008] … Biapenem has been used in trials studying the treatment of various bacterial infections.
Bezitramide
go.drugbank.com/drugs/DB01459ApprovedIllicitWithdrawnAfter cases of fatal overdose in the Netherlands in 2004 the drug was withdrawn from the market. Bezitramide has never been FDA approved and is currently a schedule II drug. … Bezitramide is a narcotic analgesic which was discovered in 1961, clinically tested around the 1970's [A14383], and marketed under the name Burgodin.
Veltuzumab
go.drugbank.com/drugs/DB05656InvestigationalVeltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.
KD7040
go.drugbank.com/drugs/DB05214InvestigationalIt is being developed by Kalypsys. … KD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07.